Pharmacological inhibition with the ataxia telangiectasia and Rad3-relevant protein serine/threonine kinase (ATR; also referred to as FRAP-related protein (FRP1)) has emerged for a promising method for cancer treatment that exploits synthetic lethal interactions with proteins linked to DNA harm maintenance, overcomes resistance to other therapies and enhances antitumour immunity. Many https://soichirom888gtf3.wikiconverse.com/user